Samsung Bioepis' bone loss biosimilar gains domestic approval

1 year ago 1486

Samsung Bioepis said Sunday its biosimilar treatment for osteoporosis and bone loss has won approval from Korea's Ministry of Food and Drug Safety.

Source: koreatimes.co.kr

Read Entire Article Source

To remove this article - Removal Request